Erratum: Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction? (Nature Clinical Practice Cardiovascular Medicine (2006) vol. 3 (182-183) doi: 10.1038/ncpcardio0508);Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 4, 2006, Pages 182-183

  Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aspirin; Clopidogrel; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AZD 6140; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEART REINFARCTION; HUMAN; MORTALITY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SHORT SURVEY; ST SEGMENT ELEVATION; STROKE; THROMBOCYTE AGGREGATION INHIBITION;

EID: 33645422948     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0657     Document Type: Erratum

References (5)

1. Fathi RB and Bhatt DL (2005) Enhancing reperfusion therapy for myocardial infarction with dual antiplatelet therapy: Breaking the glass ceiling. Am Heart J 149: 947-949
2. Sabatine MS et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179-1189
3. Yusuf S et al. (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494-502
4. Bhatt DL and Topol EJ (2004) Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 148: 263-268
5. Bhatt DL and Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2: 15-28